For instance, “anti-insulin resistance therapy”, including glucagon like peptide-1 (GLP-1) receptor agonists, has been successful in pilot studies of PD, and studies are planned for AD and other neurodegenerative diseases.4 Even though both are recognized as important facets in the development of future treatments for neurodegenerative disease, either treatment method alone may not be sufficient to overcome the relevant pathogenic processes. This evidence concerns the gene GLP1R and neurodegenerative disease.